COVID-19 in 3 patients treated with immune checkpoint inhibitors for advanced melanoma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F22%3A43920660" target="_blank" >RIV/00064173:_____/22:43920660 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11120/22:43920660

Result on the web

<a href="https://doi.org/10.1080/09546634.2020.1822500" target="_blank" >https://doi.org/10.1080/09546634.2020.1822500</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/09546634.2020.1822500" target="_blank" >10.1080/09546634.2020.1822500</a>

Result language

angličtina

Original language name

COVID-19 in 3 patients treated with immune checkpoint inhibitors for advanced melanoma

Original language description

The COVID-19 pandemic has changed the therapeutic algorithm for many dermatological diseases, particularly those where drugs are influencing the immune system. Patients with advanced melanoma are treated with immunotherapy or targeted therapy in an adjuvant or palliative regimen. There are only a few guidelines suggesting the approach to these patients, many are being treated on an individual basis. According to the National Comprehensive Cancer Network guidelines, initiation of immunotherapy/targeted therapy for metastatic disease or in an adjuvant setting is still recommended during the COVID-19 pandemic. Immune checkpoint blockade activates the immune system by enhancing T-cell proliferation and cytokine production. The extent to which an activated immune response may influence the clinical course of COVID-19 or whether it induces or enhances a hyperinflammatory reaction, is currently unknown. We evaluated 104 patients currently being treated with immunotherapy for advanced melanoma. In 76 patients the therapy was ongoing, while in 28 patients the treatment was initiated during the pandemic. Individuals were treated in an adjuvant or palliative setting with anti-PD-1 monotherapy (nivolumab/pembrolizumab), combo treatment (ipilimumab + nivolumab) or triplet treatment (spartalizumab + dabrafenib + trametinib).

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30216 - Dermatology and venereal diseases

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of Dermatological Treatment

ISSN

0954-6634

e-ISSN

1471-1753

Volume of the periodical

33

Issue of the periodical within the volume

3

Country of publishing house

GB - UNITED KINGDOM

Number of pages

2

Pages from-to

1782-1783

UT code for WoS article

000581153000001

EID of the result in the Scopus database

2-s2.0-85093683241